(Q43692733)

25 November 2017

title

Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study (English)

1 reference

systemic lupus erythematosus

25 November 2017

1 reference

1 reference

C F Remer

1 reference

25 November 2017

M H Weisman

series ordinal

1 reference

25 November 2017

D J Wallace

series ordinal

1 reference

25 November 2017

publication date

1 January 2001

1 reference

25 November 2017

1 reference

25 November 2017

1 reference

25 November 2017

1 reference

25 November 2017

page(s)

480-483

1 reference

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F096120301678416033

Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120301678416033

Validity and reliability of retrospective assessment of disease activity and flare in observational cohorts of lupus patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120301678416033

The 1982 revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120301678416033

Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120301678416033

10.1191/096120301678416033

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference